Hyperthermia Therapy Market Global Report 2026

The hyperthermia therapy market size has grown strongly in recent years. It will grow from $0.25 billion in 2025 to $0.27 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to growing prevalence of cancer cases, increasing adoption of hyperthermia as an adjunct cancer therapy, rising demand for minimally invasive treatment options, expanding oncology infrastructure, increasing clinical research activities for thermal therapy applications.

The hyperthermia therapy market size is expected to see strong growth in the next few years. It will grow to $0.38 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing integration of precision medicine approaches, rising demand for personalized oncology treatments, growing adoption of advanced thermometry systems, expanding use of combination treatment strategies, increasing investment in next-generation hyperthermia devices. Major trends in the forecast period include increasing adoption of advanced heat delivery technologies, growing development of personalized hyperthermia treatment protocols, rising integration of real-time temperature monitoring systems, expansion of combination therapies with radiation and chemotherapy, increasing demand for non-invasive thermal treatment approaches.

The increasing cancer incidence is expected to drive the growth of the hyperthermia therapy market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body, which can invade surrounding tissues and interfere with normal organ functions. The rising cancer incidence is influenced by the increasing prevalence of risk factors such as aging populations, unhealthy lifestyles, and exposure to environmental hazards, resulting in a greater number of cancer cases and increasing the need for advanced diagnostic and treatment solutions. The growing prevalence of cancer is driving demand for hyperthermia therapy, as it is used in combination with chemotherapy and radiotherapy to enhance treatment effectiveness and improve patient outcomes. For instance, in July 2026, according to the World Health Organization (WHO), a Switzerland-based UN agency, annual new cancer cases reached 20.6 million in 2024 and are expected to increase to nearly 35 million by 2050, representing an increase of almost 70%. Therefore, the increasing cancer incidence is expected to support the growth of the hyperthermia therapy market.

Leading companies operating in the hyperthermia therapy market are increasingly prioritizing magnetic nanoparticle-mediated hyperthermia systems to advance precision cancer treatment, improve therapeutic outcomes, and expand research into minimally invasive oncology solutions. Magnetic nanoparticle-mediated hyperthermia systems utilize magnetic nanoparticles activated by alternating magnetic fields to generate localized heat within tumors, enabling targeted cancer cell destruction while minimizing damage to surrounding healthy tissues and supporting combination therapies. For example, in February 2026, Mayo Clinic, a US-based academic medical center, collaborated with New Phase Ltd., an Israel-based medical technology company, to install the first magnetic nanoparticle-mediated hyperthermia system for cancer research in the United States. The investigational system is designed to support research assessing the safety, feasibility, and potential effectiveness of magnetic nanoparticle hyperthermia in cancer treatment. It enables targeted heat-based therapy and advances clinical research. The magnetic nanoparticle-mediated hyperthermia system supports the development of innovative cancer treatment approaches and accelerates the adoption of precision hyperthermia therapy.

In October 2023, Andromedic, an Italy-based company specializing in capacitive hyperthermia devices, entered into a collaboration with Sensius to enhance the advancement of hyperthermia and thermotherapy solutions in the Italian market. Through this collaboration, Andromedic and Sensius focused on increasing the adoption of hyperthermia and thermotherapy in Italy by promoting clinical studies, collaborating with oncology organizations, and supporting the development of reimbursement frameworks. Sensius is a Netherlands-based company that develops precision hyperthermia therapy systems.

Major companies operating in the hyperthermia therapy market report are Chongqing Haifu Medical Technology Co. Ltd., RanD Biotech S.r.l., Combat Medical Ltd., Pyrexar Medical Inc., Oncotherm Kft., Celsius42 GmbH, Elmedical Ltd., Thermofield, Shanghai Huayuan Electronic Co. Ltd., Dr. Sennewald Medizintechnik GmbH, Sensius B.V., Andromedic S.r.l., innoMedicus Ltd., ThermaSolutions Inc., Von Ardenne Institut GmbH, Gamida Ltd., Yamamoto Vinita Co. Ltd., Hydrosun Medizintechnik GmbH, Verthermia.

North America was the dominant region in the hyperthermia therapy market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the hyperthermia therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hyperthermia therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.